Slide 1: Virtual KOL Event November 9, 2023
Virtual KOL Event November 9, 2023 ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially i
Slide 3: Featured Speakers
Featured Speakers ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Note: Dr. David R. Lally and Dr. David S. Boyer are paid consultants to EyePoint and are being compensated for their time in connection with this event. David R. Lally, M.D. Retinal Surgeon at Baystate Medical Center Assista
Slide 4: Agenda
Agenda ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. PRESENTATION SPEAKER Introductions Jay Duker, M.D. Presentation: EYP-1901 in Wet AMD Jay Duker, M.D. Key Opinion Leader Insights and Discussion Jay Duker, M.D. David S. Boyer, M.D. David R. Lally, M.D. Q&A All Closing Remarks Jay Duker
Slide 5: Company Overview
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Company Overview Jay Duker, M.D. President and CEO
Slide 6: Company Overview
COMPANY OVERVIEW ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Pipeline represents multi billion-dollar opportunities using our bioerodible Durasert E™ intravitreal (IVT) delivery technology EYP-1901 –vorolanib, a patented tyrosine kinase inhibitor (TKI) Topline Phase 2 data in wet AMD a
Slide 7: There is a Significant Need for More Durable Therapies in Wet AMD
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. There is a Significant Need for More Durable Therapies in Wet AMD Many patients with wet AMD are chronically undertreated >80% of Retina Specialists say undertreatment is due to patient noncompliance, scheduling limitations or provider prefer
Slide 8: EYP-1901 a potential sustained delivery 6-month treatment for wet AMD
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. EYP-1901 a potential sustained delivery 6-month treatment for wet AMD Jay Duker, M.D. President and CEO
Slide 9: Vorolanib – a potential new MOA to the treatment of wet AMD
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Insert ~1/5000 of vitreous volume Vorolanib – a potential new MOA to the treatment of wet AMD Sustained release with zero order kinetics blocking all isoforms of VEGF Immediately bioavailable, featuring an initial burst of drug followed by ne
Slide 10: Vorolanib Brings a New MOA to the Treatment of VEGF-Mediated Retinal Diseases
Vorolanib Brings a New MOA to the Treatment of VEGF-Mediated Retinal Diseases by Blocking all Isoforms of VEFG as well as PDGF ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. SoC, standard of care; ANG, angiopoietin; PDGF(R), platelet-derived growth factor (receptor); PLGF, placental growt
Slide 11: DAVIO Phase 1 Clinical Trial in Wet AMD
DAVIO Phase 1 Clinical Trial in Wet AMD Enrollment Summary ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. TEAE, treatment emergent adverse events; BCVA, best corrected visual acuity; CST, central subfield thickness Multicenter, open-label, single-injection dose-escalation Enrolled patient
Slide 12: EYP-1901 Phase 1 DAVIO Clinical Trial Met All Objectives
EYP-1901 Phase 1 DAVIO Clinical Trial Met All Objectives And Informed Phase 2 Design ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *Retrospective analysis of nine subjects with no excess fluid at screening POSITIVE EFFICACY & DURABILITY Endpoint (6-month) DAVIO DAVIO Subgroup Analysis* C
Slide 13: EYP-1901 Is Positioned As A Potential Maintenance Therapy In Wet AMD
EYP-1901 Is Positioned As A Potential Maintenance Therapy In Wet AMD ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Treat wet AMD patients with anti-VEGF of choice to reach desired “dry” outcome and maximize visual improvement Maintain with EYP-1901, a new MOA with sustained delivery and
Slide 14: EYP-1901 May Provide Greater Flexibility in Managing Patients
Tailor dosing schedule to patient needs Manage the disease with different, complementary MOAs Potentially treat a chronic disease with both short- and long-acting drugs Optimize patient visit and flow EYP-1901 May Provide Greater Flexibility in Managing Patients 14
Slide 15: EYP-1901 in Wet AMD DAVIO 2 Clinical Trial Update
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. EYP-1901 in Wet AMD DAVIO 2 Clinical Trial Update
Slide 16: The DAVIO 2 clinical trial was designed to support initiation of Phase 3
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. The DAVIO 2 clinical trial was designed to support initiation of Phase 3 clinical trials based on a Type C meeting with FDA Objective: Evaluate efficacy and safety of a single injection of two doses of EYP-1901 Key changes in enrollment from
Slide 17: DAVIO 2 Is A Randomized, Double-Masked, Aflibercept Controlled Trial
EYP-1901 DAVIO 2 Clinical Trial Is A Randomized, Double-Masked, Aflibercept Controlled* With A Single EYP-1901 Treatment At Two Doses ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. -D14 to -D7 D1 W4 W8 W12 W16 W24 W32 W36 to W56 W20 W28 EYP-1901 2mg low dose EYP-1901 3mg high dose Afliber
Slide 18: EYP-1901 Continues to Show a Favorable Safety Profile
EYP-1901 Continues to Show a Favorable Safety Profile Across Multiple Clinical Trials Through October 1, 2023 ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *Data are preliminary results, pending study completion and final report. SAE, serious adverse event Summary: DAVIO (Phase 1): 17 pa
Slide 19: Masked Patient Demographic Reflects A More Stable Population in DAVIO 2
Masked Patient Demographic Reflects A More Stable Population in DAVIO 2 Compared to the DAVIO Phase 1 Trial ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *DAVIO Final 12-month data; **DAVIO 2 unmonitored data cut as of October 1, 2023 Phase 1 DAVIO Baseline Characteristics (N = 17)* Mean
Slide 20: Outcome Scenarios for DAVIO 2 Primary Endpoint
Outcome Scenarios for DAVIO 2 Primary Endpoint of Non-Inferior Change in BCVA to Aflibercept ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. *Numerically the same or better than HD Eylea (16-week 8 mg Eylea arm in the Pulsar trial). FDA defined the lower bound for non-inferiority as -4.5 l
Slide 21: DAVIO 2 Outcomes: Lower Limit Ranges to Support Potential Phase 3 Trials
DAVIO 2 Outcomes: Lower Limit Ranges to Support Potential Phase 3 Trials ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. 1. The FDA defines the lower limit of the non-inferiority margin as a -4.5-letter loss. Favorable safety profile < -3 letters change in visual acuity difference between
Slide 22: Reduction in Treatment Burden is an Important Secondary Outcome
Reduction in Treatment Burden is an Important Secondary Outcome Given the Unmet Need in wet AMD for More Durable Therapies ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Treatment burden = Number of injections an eye receives for the 24-week period following EYP-1901 dosing or sham inject
Slide 23: Key Opinion Leader Insights and Discussion
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Key Opinion Leader Insights and Discussion EYP-1901 in wet AMD and Topline Data Considerations for the DAVIO 2 Clinical Trial
Slide 24: Q&A
©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Q&A
Slide 25: Virtual KOL Event November 9, 2023
Virtual KOL Event November 9, 2023 ©2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved.